Xeris Biopharma Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xeris Biopharma Holdings (XERS).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

6Buy

1Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$11Upside to Avg. PT+13.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$12→$14
Sep 10, 2026	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$12→$16
Aug 20, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$9→$12
Mar 2, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Jan 9, 2026	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$9
Nov 7, 2025	Oppenheimer	Leland Gershell	Maintained	Outperform	$18
Nov 7, 2025	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Nov 7, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$6→$8
Oct 29, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$8→$18
Sep 17, 2025	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
Aug 19, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$7→$9
Aug 12, 2025	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$10
Aug 8, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$7→$11
Aug 8, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$7→$8
Jun 5, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$6→$7
May 9, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$6→$7
Mar 7, 2025	Oppenheimer	Leland Gershell	PT Raise	Outperform	$5→$6
Mar 7, 2025	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$5→$6
Mar 7, 2025	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$5→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Leerink Partners analyst Roanna Ruiz maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $12 to $16.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight rating and announces Price Target of $9.

Benzinga Newsdesk

Xeris Biopharma Holdings Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Xeris Biopharma Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

People Also Watch

People Also Watch

Xeris Biopharma Holdings Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Xeris Biopharma Holdings Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PROLeerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

PROHC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PROHC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PROBarclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

People Also Watch

People Also Watch

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9